Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective.

ABSTRACT:

Introduction

Golimumab is a tumor necrosis factor-α (TNF-α) inhibitor for treatment of patients with severe, active ankylosing spondylitis. This study evaluated the cost-effectiveness of golimumab compared with conventional care and other TNF-α inhibitors in treatment of AS from the UK National Health Service perspective.

Methods

A long-term Markov model (with initial decision tree) was developed to simulate the progression of a hypothetical cohort of patients with active AS over a lifetime. The effectiveness outcome was quality-adjusted life-years (QALYs). Utilities were estimated by mapping Bath Ankylosing Spondylitis Functional Index scores, and the primary response measure was ≥50% improvement on the Bath Ankylosing Spondylitis Disease Activity Index at 12 weeks. Direct,

SUBMITTER: Borse RH 

PROVIDER: S-EPMC5696295 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature